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A B S T R A C T
Objective: To report a diagnosis of hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome following
initial presentation with multiple cutaneous lesions.
Design: Case report.
Design classiﬁcation: N/A.
Setting: Academic tertiary care center.
Patient(s): 27-year-old nulligravid woman who presented with multiple red-brown lesions on her skin found to
have cutaneous and uterine leiomyoma.
Intervention(s): Biopsy of cutaneous lesions and fertility sparing robot-assisted laparoscopic myomectomy
(RALM).
Main outcome measures(s): Histological assessment of uterine leiomyoma.
Results(s): Pathologic examination of uterine leiomyoma revealed diﬀuse atypia and fumarate hydratase loss
phenotype concerning for genetic syndrome. Follow-up DNA sequencing via Sanger sequencing conﬁrmed a
pathogenetic R2333H mutation consistent with HLRCC.
Conclusion(s): Consideration of HLRCC on diﬀerential diagnosis when patients present with cutaneous nodules
and atypical or early onset uterine leiomyoma provides opportunity for early surveillance, family member
testing, and more thoughtful surgical planning.
Precis: 27-year-old woman with multiple cutaneous lesions is found to have uterine leiomyomas and undergoes
robotic myomectomy. Genetic testing of uterine leiomyomas reveals mutation in fumarate hydratase, etiologic in
hereditary leiomyomatosis and renal cell cancer (HLRCC).
1. Introduction
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syn-
drome is an autosomal dominant disorder caused by a germ line mu-
tation in FH, encoding the Krebs cycle enzyme fumarate hydratase.
Mutations in FH have been described in over 100 families worldwide,
and various genotype-phenotype relationships have been suggested
involving tumor suppression [1]. Uterine leiomyomas are a common
gynecologic tumor present in up to 77% of reproductive age women
[2]. HLRCC, characterized by multiple cutaneous and uterine leio-
myomas, predisposes for aggressive papillary type II renal cell carci-
noma and, rarely, leiomyosarcoma (LMS) [3,4]. This rare genetic con-
dition likely remains undiagnosed in many individuals, as the
appearance of cutaneous nodules is often a non-speciﬁc and under in-
vestigated clinical ﬁnding. Herein, we describe a case in which cuta-
neous lesions in a young woman prompted further evaluation leading to
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an eventual diagnosis of HLRCC.
2. Case Report
A 27-year-old, nulligravid woman presented to her primary care
physician with multiple red-brown, raised maculopapular lesions. She
ﬁrst reported developing these lesions on her back ﬁve years prior to
presentation. On exam, multiple nodular and non-tender lesions were
noted (Fig. 1). Her medical history was signiﬁcant only for an un-
repaired ventricular septal defect. She did not report any surgical his-
tory or use of prescription medications. In consultation with a derma-
tologist, who believed the lesions to be keloids or cysts, a nodule was
biopsied. Dermatopathology conﬁrmed cutaneous leiomyomata. During
the interval of evaluation and biopsy, she developed new lesions on her
arms, chest, and thighs.
Given clinical suspicion for HLRCC, a more thorough family history
revealed a paternal history of renal cell and basal cell carcinoma as well
as maternal uterine leiomyoma. As part of her clinical evaluation for
HLRCC, kidney function was assessed with serum labs, revealing a
creatinine of 0.95 mg/dl and hyperkalemia of 5.4 mmol/L. A renal MRI
did not demonstrate any masses. Additionally, a pelvic ultrasound was
performed, given an enlarged uterus on pelvic examination. Initial ul-
trasound demonstrated a ﬁbroid uterus, and due to concern for LMS in
HLRCC patients, an MRI was ordered. The MRI identiﬁed a subserosal,
pedunculated leiomyoma measuring 8.3 cm in diameter and multiple
submucosal and intramural leiomyoma, with the largest measuring
4.0 cm (Fig. 2).
Given the patient's desire for fertility-sparing surgery and the need
to rule out a malignant uterine tumor by histologic diagnosis of pre-
sumptive HLRCC, the patient opted for a myomectomy. She underwent
a robot-assisted laparoscopic myomectomy (RALM) with resection of
four leiomyoma measuring a total of 90 g. Her leiomyoma were re-
moved using uncontained power morcellator, which was considered
standard of care at our hospital the time of the operation. Her post-
operative course was complicated by a surgical site infection growing
Pseudomonas aeruginosa treated with a 14-day course of oﬂoxacin with
complete resolution.
On pathologic examination, the tissue was noted to display diﬀuse
atypia and show nuclear features typically associated with leiomyoma
in patients with HLRCC. The patient was referred for genetic testing for
mutations in FH. DNA sequence analysis of a peripheral blood sample
via Sanger sequencing of FH revealed a heterozygous G > A nucleotide
substitution in exon 5, resulting in the replacement of an arginine
codon with a histidine codon at amino acid position 233, referred to as
R233H at the DNA level (also referred to as R190H in the mutated,
truncated protein).
Her uterine leiomyoma were also evaluated for features of HLRCC
syndrome. Histopathologic examination by hematoxylin and eosin
staining and immunostaining for fumarate hydratase (fumarate hy-
dratase, sc-100743, Santa Cruz Biotechnology, Inc.) revealed a typical
“FH loss” phenotype (Fig. 3). Sanger sequencing of uterine leiomyoma
was performed using ampliﬁed PCR products (QIAamp DNA FFPE
Tissue Kit (56404)) with identiﬁcation of the pathogenetic R233H
mutation.
3. Discussion
While uterine leiomyomas are common, HLRCC is rare, and diag-
nosing the syndrome is important not only for the aﬀected individual
but her entire family. The R233H (or R190H) missense mutation in FH,
located on the long arm of chromosome 1 in band q43, is one of many
mutations linked to hereditary leiomyomatosis and renal cell cancer
(HLRCC). This autosomal dominant disorder results from a defective FH
enzyme, which is involved in the Krebs cycle and thus plays a role in
cellular metabolism. It is suspected that the inactivated protein, due to
a missense mutation, inactivates a highly conserved tumor suppressor,
which can lead to benign leiomyomas and aggressive kidney cancer
[5,6]. In a particular patient subset of Finnish descent, FH mutations
were also linked to increased risk of early onset uterine leiomyosarcoma
[4,7].
For female patients with a family history of atypical uterine ﬁbroids,
early age of onset of ﬁbroids, or a combination of uterine ﬁbroids and
cutaneous lesions, genetic testing for a mutation in FH may be an im-
portant testing strategy. Furthermore, a positive genetic test for FHmay
prompt earlier screening for renal cell neoplasms in the patient and
family members. Dedicated renal MRI or CT scans with intravenous
contrast are recommended for early detection of aggressive renal tu-
mors as their diagnostic accuracy and utility far exceed that of renal
ultrasound when there is a high degree of suspicion for renal cancer [8].
Lifetime risk for renal cell cancer in HLRCC patients is estimated to be
15% for men and women [9]. Aﬀected women may have even greater
risk for RCC than their aﬀected male family members [8].
Awareness of an HLRCC phenotype and genetic testing for FH can be
critical to optimal patient management, especially as morphological
identiﬁcation of HLRCC-associated tumors by histopathology may be
inconsistent [10]. We now recognize that uterine leiomyoma with FH
mutations have a characteristic microscopic appearance, including
prominent enlarged, orangeophilic nucleoli, surrounded by clearing of
the nuclear chromatin, usually associated with a recognizable, albeit
low level nuclear atypia (slightly enlarged nuclei and slightly coarser
chromatin) and sometimes eosinophilic cytoplasmic inclusions. Tradi-
tionally, S-(2-succinyl) cysteine (S2C) overexpression using anti-2SC
antibodies and appearance of eosinophilic nucleoli have been used as a
biomarker for HLRCC-associated tumors [11,12]. However, the use of
anti-FH antibodies has been shown to be a readily available and reliable
alternative for HLRCC screening on tissue specimens.
Once a diagnosis is made a careful surveillance and treatment plan
should be discussed with the patient. Given that a large percentage of
patients with HLRCC are likely of reproductive age, early diagnosis and
monitoring allows for a more thoughtful discussion on medical man-
agement and fertility sparing surgery. In the case of our patient, she was
able to conceive spontaneously one year after her RALM and delivered
via cesarean section at 38 weeks. When considering myomectomy, the
link between HLRCC and LMS, albeit rare, should give surgeons pause
before proceeding with surgical management.
When there is clinical suspicion for occult malignancy, hyster-
ectomy, or en bloc resection of the uterus, is the preferred surgical
option. In one study, 89% of women with cutaneous and uterine leio-
myomas underwent hysterectomy, of which 57% were under the age of
30 years [8]. Myomectomy allows patients to preserve fertility, and
elect for deﬁnitive surgery after the completion of childbearing. How-
ever, myomectomy also implies acknowledgement by the patient and
Fig. 1. Photograph of the patients mid back demonstrating multiple, nodular sub-
cutaneous leiomyoma.
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the surgeon that an occult LMS may be disseminated thus potentially
upstaging of occult LMS within the abdomen and pelvis when morcel-
lation is performed [13]. The prevalence of LMS in women undergoing
hysterectomy or myomectomy for presumed benign indications is es-
timated at 0.2% (1 in 458) by the FDA [14]. Contained morcellation has
been proposed as a risk reducing strategy in patients opting for
myomectomy. However, even when contained morcellation is em-
ployed, tissue or dye dissemination has been reported in up to 9.7% of
cases [15]. Thus, when considering surgical management, a discussion
with the patient regarding the risk of occult malignancy as well as risk
reducing strategies is an important part of an informed consent process.
In women with atypical skin ﬁndings and ﬁbroids a consideration of
Fig. 2. MRI of abdomen and pelvis with and without con-
trast: Sagittal T2 images demonstrating a 4 × 4× 3 cm
intramural, fundal ﬁbroid with submucosal component (A)
and 8 × 6× 5 cm heterogeneous, right, subserosal ﬁbroid
with broad connection to the uterus (B). Axial T2 image
demonstrating both 4 cm intramural and 8 cm right, sub-
serosal ﬁbroids (C). Coronal T2 image demonstrating both
4 cm intramural, fundal and 8 cm right, subserosal ﬁbroid
(D).
Fig. 3. Histology of the uterine leiomyomas removed from
the subject demonstrating diﬀuse mild-moderate nuclear
atypia and large cherry red nucleoli with distinct clearing of
the coarsely granular chromatin around the nucleoli (arrow
with long stem) (A, B). Immunohistochemistry with an
antibody for fumarate hydratase demonstrated essentially
complete loss of protein staining in the neoplastic smooth
muscle cells in the subject. Eosinophilic cytoplasmic in-
clusions (arrow with short stem) and granular cytoplasmic
staining reﬂecting mitochondrial localization were also
evident in the non-neoplastic endothelial and vascular
smooth muscle cells within the subject's tumor (C). As a
positive control, immunohistochemistry was performed on
an atypical leiomyomata without the histological pheno-
type of HLRCC from an unrelated individual, revealing ty-
pical granular cytoplasmic staining pattern for fumarate
hydratase expression (D).
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HLRCC in the diﬀerential diagnosis is warranted. A thorough physical
examination and in-depth family history can raise suspicion for this
heritable disorder. If palpable cutaneous lesions or renal masses are also
present, they should biopsied and analyzed for histopathologic and
immunopathologic ﬁndings of HLRCC. Finally, gynecologists should
consider genetic testing and management for HLRCC in the same
manner in which they care for women with endometrial cancer with a
diagnosis of Lynch syndrome. When suspicion or knowledge of such a
diagnosis is made, pre-operative planning should take this into con-
sideration when considering tissue containment and removal.
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